Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the mrna cancer vaccines and therapeutics market?
The market for mRNA cancer vaccines and therapeutics has seen a swift expansion in the past few years. The market, valued at $61.52 billion in 2024, is predicted to reach $71.85 billion in 2025, representing a compound annual growth rate (CAGR) of 16.8%. The significant expansion in the previous timeframe is associated with lifestyle changes, financial backing, a conducive regulatory setting, robust healthcare infrastructure, and an uptick in pipeline development.
What will be the mrna cancer vaccines and therapeutics market size in the future?
The market size of mRNA cancer vaccines and therapeutics is set to expand rapidly in the upcoming years. The projection shows a rise to $131.99 billion in 2029 with a compound annual growth rate (CAGR) of 16.4%. The forecasted growth can be linked to positive results from clinical trials, increased understanding and acceptance of mRNA technology, unresolved needs in cancer treatments, the possibility for better patient results, and potential for readiness off-the-shelf. Major trends expected in the future include branching into novel therapeutic areas, adoption of personalized medicine, advancements in delivering mRNA, multivalent mRNA vaccines, and the use of artificial intelligence and machine learning in mRNA design.
Get your mrna cancer vaccines and therapeutics market report here!
What main drivers are fueling expansion in the mrna cancer vaccines and therapeutics market?
The increasing incidence of cancer is anticipated to fuel the expansion of the mRNA cancer vaccine and therapeutic market. Cancer encompasses a range of diseases typified by uncontrolled growth and dissemination of abnormal cells which transgress and demolish healthy body tissue. Sedentary life choices, an unhealthy diet, and exposure to environmental toxins have led to the rising prevalence of cancer. mRNA cancer vaccines and treatments are required to offer individualized, targeted solutions which strengthen the immune system’s capacity to identify and combat cancer cells, boosting the effectiveness of treatment and patient prognosis. For example, data from the American Cancer Society, a non-profit organization in the US focused on fighting cancer, revealed in January 2023, that the estimated number of new cancer cases had risen from approximately 1,918,030 in 2022 to 1,958,310 in 2023 in the United States. Breast cancer is the primary chronic condition in the country, with cases increasing from 287,850 in 2022 to 297,790 in 2023. Thus, the rising incidence of cancer is stimulating the growth of the mRNA cancer vaccine and therapeutic market.
What key areas define the segmentation of the global mrna cancer vaccines and therapeutics market?
The mRNA cancer vaccines and therapeutics market covered in this report is segmented –
1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Infectious Disease, Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users
Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp
Who are the dominant players expanding their reach in the mrna cancer vaccines and therapeutics market?
Major companies operating in the mRNA cancer vaccines and therapeutics market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, Sanofi AG, AstraZeneca Plc, GlaxoSmithKline Plc, Hoffmann-La Roche AG, Eli Lilly and Company, Moderna Therapeutics Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Catalent Inc., Sarepta Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Genentech Inc., Immatics Biotechnologies GmbH, CureVac N.V, Anima Biotech, Argos Therapeutics Inc.
What key trends are currently impacting the mrna cancer vaccines and therapeutics market’s development?
Leading entities in the mRNA cancer vaccine and therapeutics market are concentrating their efforts on developing novel remedies like mRNA cancer vaccines, which promise enhanced efficiency, better patient results, and provide solutions to the increasing need for successful cancer treatments. Through the use of messenger RNA, mRNA cancer vaccines, an immunotherapy form, guide cells in creating certain antigens, enabling the immune system to identify and combat cancer cells. An example of this occurred in May 2024, when WestGene Biopharma, a China-based biotech firm, obtained FDA approval for its new investigational drug application, the mRNA therapeutic cancer vaccine, WGc-043. The FDA’s authorization of WGc-043 signifies a significant development in the therapy of severe EB virus-associated cancers, which are closely connected to ten plus malignancies, like nasopharyngeal carcinoma, NK T-cell lymphoma, as well as gastric, lung, liver, esophageal, breast, and cervical cancers. It also has potential applications for autoimmune diseases such as multiple sclerosis and lupus.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17204
Which regions are emerging as leaders in the mrna cancer vaccines and therapeutics market?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mRNA cancer vaccines and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Lung Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Breast Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
Cancer Diagnostics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
